Gentian Diagnostics ASA
OSE:GENT
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
35.8
59
|
| Price Target |
|
We'll email you a reminder when the closing price reaches NOK.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Gentian Diagnostics ASA
Other Current Liabilities
Gentian Diagnostics ASA
Other Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
G
|
Gentian Diagnostics ASA
OSE:GENT
|
Other Current Liabilities
kr21.6m
|
CAGR 3-Years
-3%
|
CAGR 5-Years
38%
|
CAGR 10-Years
N/A
|
|
Gentian Diagnostics ASA
Glance View
Gentian Diagnostics ASA is a medical diagnostics company. The company is headquartered in Moss, Ostfold. The company went IPO on 2016-12-14. The firm develops and manufactures in vitro diagnostic (IVD) products for the detection and quantification of specific markers for use on a wide range of clinical chemistry analysers. The Company’s product portfolio comprises turbidimetric fecal calprotectin immunoassay, which is to be run on clinical chemistry analysers: The Gentian Calprotectin Immunoassay, Cystatin C, NT-proBNP - Pre-launch, SARS-CoV-2 Ab Pre-Launch, Canine CRP and Beckman Coulter Customers. The firm is based in Moss, Norway, serving the global human and veterinary diagnostics markets through sales and representative offices in Sweden, USA and China.
See Also
What is Gentian Diagnostics ASA's Other Current Liabilities?
Other Current Liabilities
21.6m
NOK
Based on the financial report for Jun 30, 2024, Gentian Diagnostics ASA's Other Current Liabilities amounts to 21.6m NOK.
What is Gentian Diagnostics ASA's Other Current Liabilities growth rate?
Other Current Liabilities CAGR 5Y
38%
Over the last year, the Other Current Liabilities growth was -8%. The average annual Other Current Liabilities growth rates for Gentian Diagnostics ASA have been -3% over the past three years , 38% over the past five years .
You don't have any saved screeners yet
